Mirador Therapeutics has announced its launch after securing more than $400m from leading life sciences investors.
The US-based company will focus on developing precision medicines for immune-mediated inflammatory and fibrotic diseases.
Founded by chairman and CEO Mark McKenna, Mirador is headed by a group of former executives from Prometheus Biosciences and aims to transform the treatment landscape for immune-mediated diseases.
Mirador's development engine, Mirador360, is at the core of its strategy to rapidly progress multiple programmes.
ARCH Venture Partners led the financing for Mirador with significant early investments from OrbiMed and Fairmount.
The funding round also saw contributions from a consortium of top-tier investors, including Fidelity Management & Research, Farallon Capital Management, Point72, TCGX and Invus.
Mirador will focus on the development of precision medicines using Mirador360, which fast-tracks the process by leveraging advancements in human genetics and data science.
Mirador360 can analyse millions of patient molecular profiles. This analysis aids in discovering and verifying genetic links to immuno-fibrotic ailments, identifying new therapeutic targets and understanding interactions between targets, potentially leading to the development of combination therapies.
The platform enables the company to create diagnostics and stratify patient populations, ensuring precise clinical development.
McKenna stated: “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy.
“The industry has only scratched the surface of utilising advances in human genetics – coupled with exponential progress in machine learning – to accelerate the development of precision therapies for patients who need them the most.
“With a proven team, distinguished board of directors, leading healthcare investors and proprietary data-driven approach, we aim to create a leading precision medicine company at scale to provide important new treatment options for patients.”
